Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1962 3
1963 1
1964 1
1965 1
1967 1
1968 1
1969 3
1971 1
1972 1
1974 4
1975 9
1976 3
1977 4
1978 2
1979 5
1980 2
1981 1
1982 6
1983 4
1984 8
1985 11
1986 9
1987 18
1988 23
1989 32
1990 26
1991 35
1992 18
1993 37
1994 33
1995 47
1996 37
1997 52
1998 48
1999 73
2000 56
2001 84
2002 102
2003 127
2004 152
2005 183
2006 188
2007 223
2008 268
2009 348
2010 388
2011 435
2012 514
2013 630
2014 645
2015 707
2016 759
2017 772
2018 833
2019 912
2020 1079
2021 1224
2022 1384
2023 1350
2024 1418
2025 917

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,498 results

Results by year

Filters applied: . Clear all
Page 1
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP, Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu RH. Shitara K, et al. Among authors: kang yk. N Engl J Med. 2024 Sep 26;391(12):1159-1162. doi: 10.1056/NEJMc2409512. Epub 2024 Sep 16. N Engl J Med. 2024. PMID: 39282934 Free PMC article. No abstract available.
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Van Dao T, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Paskow MJ, Ran D, Xynos I, Kurland JF, Negro A, Abou-Alfa GK. Rimassa L, et al. Among authors: kang yk. J Hepatol. 2025 Apr 11:S0168-8278(25)00226-0. doi: 10.1016/j.jhep.2025.03.033. Online ahead of print. J Hepatol. 2025. PMID: 40222621 Free article.
Novel Immunotherapies for Osteosarcoma.
Lu Y, Zhang J, Chen Y, Kang Y, Liao Z, He Y, Zhang C. Lu Y, et al. Among authors: kang y. Front Oncol. 2022 Apr 1;12:830546. doi: 10.3389/fonc.2022.830546. eCollection 2022. Front Oncol. 2022. PMID: 35433427 Free PMC article. Review.
Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study.
Yin X, Kim K, Suetsugu H, Bang SY, Wen L, Koido M, Ha E, Liu L, Sakamoto Y, Jo S, Leng RX, Otomo N, Kwon YC, Sheng Y, Sugano N, Hwang MY, Li W, Mukai M, Yoon K, Cai M, Ishigaki K, Chung WT, Huang H, Takahashi D, Lee SS, Wang M, Karino K, Shim SC, Zheng X, Miyamura T, Kang YM, Ye D, Nakamura J, Suh CH, Tang Y, Motomura G, Park YB, Ding H, Kuroda T, Choe JY, Li C, Niiro H, Park Y, Shen C, Miyamoto T, Ahn GY, Fei W, Takeuchi T, Shin JM, Li K, Kawaguchi Y, Lee YK, Wang YF, Amano K, Park DJ, Yang W, Tada Y, Lau YL, Yamaji K, Zhu Z, Shimizu M, Atsumi T, Suzuki A, Sumida T, Okada Y, Matsuda K, Matsuo K, Kochi Y; Japanese Research Committee on Idiopathic Osteonecrosis of the Femoral Head; Yamamoto K, Ohmura K, Kim TH, Yang S, Yamamoto T, Kim BJ, Shen N, Ikegawa S, Lee HS, Zhang X, Terao C, Cui Y, Bae SC. Yin X, et al. Among authors: kang ym. Ann Rheum Dis. 2022 Aug 11;81(9):1273-1280. doi: 10.1136/annrheumdis-2022-222345. Ann Rheum Dis. 2022. PMID: 35609976 Free PMC article.
14,498 results
You have reached the last available page of results. Please see the User Guide for more information.